Canada has granted provisional authorization for Eli Lilly’s antibody drug for the treatment of COVID-19 in patients who are not hospitalized but who are at risk of serious illness due to their age or other conditions, said Friday the drug maker.
The news comes weeks after the treatment, bamlanivimab, was approved for emergency use in the United States by the Food and Drug Administration to help newly diagnosed high-risk patients avoid hospitalization.
Bamlanivimab was developed in partnership with Canadian biotechnology company AbCellera.
The Health Canada clearance was based on a clinical study in patients with mild to moderate COVID-19, where patients treated with bamlanivimab had a viral load and reduced symptom and hospitalization rates.
The drug is a monoclonal antibody – a widely used class of biotech drugs – which in this case is a fabricated copy of an antibody that the human body creates to fight infections.
“This authorization in Canada contributes to our goal of making bamlanivimab available to patients who need it around the world and is a testament to the close collaboration between industry and governments to bring COVID-19 drugs to the people most. quickly possible, ”David A. Ricks, Chairman and CEO of Lilly, said in a statement released Friday.
WATCH | How well will COVID-19 vaccines work in the real world?